期刊
EUROPEAN JOURNAL OF HEART FAILURE
卷 12, 期 1, 页码 66-74出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurjhf/hfp172
关键词
Cost-effectiveness; Heart failure; Statins; Multinational trial
To estimate the cost-effectiveness of 10 mg rosuvastatin daily for older patients with systolic heart failure in the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) trial. This within trial analysis of CORONA used major cardiovascular (CV) events as the outcome measure. Resource use was valued and the costs of hospitalizations, procedures, and statin use compared. Cost-effectiveness was estimated as cost per major CV event avoided. There were significantly fewer major CV events in the rosuvastatin group compared with the placebo group (1.04 vs. 1.20 per patient; difference 0.164; 95% CI: 0.075-0.254, P < 0.001). The average cost of CV hospitalizations and procedures was significantly lower for those receiving rosuvastatin (1531 pound vs. 1769; pound difference 238; pound 95% CI: 73-403 pound, P = 0.005); the additional cost of the statin resulted in significantly higher total costs for the rosuvastatin group (1769 pound vs. 2072; pound difference 303; pound 95% CI: 138-468 pound, P < 0.001). Overall, rosuvastatin was found to cost 1840 pound (95% CI: 562-6028) pound per major CV event avoided. This economic analysis showed that a significant reduction in major CV events with rosuvastatin led to significantly reduced costs of CV hospitalizations and procedures. The reduction in associated costs for major CV events was found to offset partially (by 44%) the cost of rosuvastatin treatment in patients with systolic heart failure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据